Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
18.45
-1.07 (-5.48%)
May 9, 2025, 3:40 PM - Market open
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Celldex Therapeutics stock have an average target of 50.75, with a low estimate of 31 and a high estimate of 70. The average target predicts an increase of 175.07% from the current stock price of 18.45.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Celldex Therapeutics stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $36 → $31 | Hold | Maintains | $36 → $31 | +68.02% | May 9, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $46 → $43 | Buy | Maintains | $46 → $43 | +133.06% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $50 | Strong Buy | Maintains | $80 → $50 | +171.00% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +333.60% | May 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $64 | Strong Buy | Initiates | $64 | +246.88% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
3.75M
from 7.02M
Decreased by -46.64%
Revenue Next Year
3.39M
from 3.75M
Decreased by -9.40%
EPS This Year
-3.34
from -2.45
EPS Next Year
-4.01
from -3.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.6M | 12.6M | 104.1M | ||
| Avg | 3.7M | 3.4M | 41.6M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.5% | 236.4% | 2,968.4% | ||
| Avg | -46.6% | -9.4% | 1,125.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.83 | -3.01 | -2.88 | ||
| Avg | -3.34 | -4.01 | -3.83 | ||
| Low | -3.60 | -5.07 | -4.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.